Search
Insmed Inc
INSMAdd to Watchlist
98.600USD
-2.890-2.85%
Close 07-31 16:00（ET）Quotes delayed by 15 min
21.35BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Insmed Inc is 8.61, ranking 96 out of 385 in the Biotechnology & Medical Research industry. The average price target is 216.50, with a high of 256.00 and a low of 144.21.
Analyst Rating
Based on
24
analysts
Buy
Current Rating
196.965
Target Price
+91.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Insmed Inc
INSM
24
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Insmed Inc's expected revenue for the next quarter?
Insmed Inc's expected revenue is 392.49M.
What is Insmed Inc's price target?
Analysts forecast that Insmed Inc's price target is USD 216.50, with the highest forecast at USD 256.00 and the lowest forecast at USD 144.21.
How have Insmed IncINSM's recent earnings per share performed?
The market expectation was USD -0.76, while Insmed IncINSM's earnings per share (EPS) for the previous quarter was USD -1.54. EPS for the next quarter is expected at USD -0.78.
What is the analyst rating for Insmed Inc?
Based on the ratings of Insmed Inc's stock from 24 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.